BioNTech SE - ADR vs VanEck Gold Miners ETF — how do they compare? BioNTech SE - ADR trades at $93.4 (market cap $23.31B), while VanEck Gold Miners ETF trades at $91.15. The key difference: VanEck Gold Miners ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | GDX | |
|---|---|---|
Market Cap | $23.31B | — |
Sector | Health | — |
52-Week High | $119.34 | $115.84 |
52-Week Low | $83.89 | $56.60 |
Enterprise Value | $6.60B | — |
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
GDX trades at $90.92, up 0.48% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights institutional repositioning and strong gold price momentum driving miner performance. The ETF offers diversified exposure to gold mining equities, though key valuation ratios are not publicly detailed for the fund itself.
The outlook is supported by gold's rally and potential for miner catch-up, but risks include gold price volatility and sector underperformance relative to bullion. Analyst sentiment is mixed, with some seeing value in miners after recent gains, while technical indicators warn of near-term overextension.
Trailing returns across standard periods
Latest headlines on both assets
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →